Antisense & RNAi Therapeutics Market

Table of Content

1. INTRODUCTION
   1. Study Assumptions and Market Definition
   2. Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
   1. Market Overview
   2. Market Drivers
      1. Growing Focus Toward Rare Genetic Conditions and the Advancement of Customized Treatments
   3. Market Restraints
      1. Delivery Challenges
      2. High Development Costs
   4. Market Opportunities
      1. Proliferating Antisense & RNAi Therapeutics Applications Beyond Rare Disorders
   5. Market Trends
      1. Advancements in Oligonucleotide Delivery
      2. Expansion into Neurological Disorders
5. MARKET SEGMENTATION
   1. By Technology
      1. RNA Interference
      2. Antisense RNA
   2. By Application
      1. Genetic Disease
      2. Cancer
      3. Infectious Disease
      4. Neurodegenerative Disorders
      5. Cardio Metabolic & Renal Disorders
      6. Ocular Disorders
      7. Respiratory Disorders
      8. Skin Disorders
      9. Others
   3. By Route of Administration
      1. Intravenous Injections
      2. Intrathecal Injections
      3. Subcutaneous Injections
      4. Other Delivery Methods
   4. By Key Geographic Regions
      1. North America
         1. United States
         2. Canada
         3. Mexico
      2. Europe
         1. Germany
         2. United Kingdom
         3. France
         4. Italy
         5. Spain
         6. Rest of Europe
      3. Asia Pacific
         1. China
         2. Japan
         3. India
         4. Australia
         5. South Korea
         6. Rest of Asia Pacific
      4. Middle East and Africa
         1. GCC
         2. South Africa
         3. Rest of Middle East and Africa
      5. South America
         1. Brazil
         2. Argentina
         3. Rest of South America
6. COMPETITIVE LANDSCAPE
   1. Company Profile
      1. Antisense Therapeutics Limited
      2. Alnylam Pharmaceuticals, Inc.
      3. Arbutus Biopharma
      4. Bio-Path Holdings Inc.
      5. Benitec Biopharma Inc.
      6. GSK plc
      7. Ionis Pharmaceuticals, Inc.
      8. Olix Pharmaceuticals, Inc.
      9. Sanofi
      10. Silence Therapeutics

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

Frequently Asked Questions

Q.1. What is the projected market value of the global antisense & RNAi therapeutics market?

The global market of antisense & RNAi therapeutics is projected to reach USD 22.69 Bn by 2033.

Q.2. What is the estimated growth rate (CAGR) of the global antisense & RNAi therapeuticsmarket?

The global antisense & RNAi therapeutics market has an estimated annual growth rate of 18.6% .

Q.3. What are the recent trends of antisense & RNAi therapeuticsmarket?

Shift towards in-vitro methods as well as integration of Artificial Intelligenceare some of the major trends of the market that is projected to boost the market growth in the near future.

Q.4. Which are the top companies to hold the market share in antisense & RNAi therapeutics?

The major companies profiled in this report include Antisense Therapeutics Limited, Alnylam Pharmaceuticals, Inc., Arbutus Biopharma, Bio-Path Holdings Inc., Benitec Biopharma Inc., GSK plc, Ionis Pharmaceuticals, Inc., Olix Pharmaceuticals, Inc., Sanofi, Silence Therapeutics, among others.

Q.5. Which is the largest regional market in the antisense & RNAi therapeutics?

North America is the largest regional market for antisense & RNAi therapeutics.